bluebird bio, Inc.: M&A transaction — bluebird bio closes sale of rare pediatric disease PRV to argenx for $102M

bluebird bio, Inc.

Completed sale of Rare Pediatric Disease Priority Review Voucher to argenx BV for $102M cash.
PRV awarded under FDA program for SKYSONA approval for cerebral adrenoleukodystrophy.
Transaction closed on Dec 29, 2022 after HSR waiting period expiration.
Terms consistent with previously disclosed Asset Purchase Agreement from Nov 29, 2022.

item 2.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

bluebird bio, Inc. completed a disposition involving argenx BV for $102.0 million in cash (closed 2022-12-29).

Action: disposition
Counterparty: argenx BV
Consideration: $102.0 million in cash
Closing: 2022-12-29

Exact text from the filing

Report on Form 8-K filed with the Securities and Exchange Commission on November 30, 2022 (the “Prior 8-K”). Pursuant to the PRV Transfer Agreement, Buyer paid the Company $102.0 million in cash upon the closing of the Asset Sale. The foregoing description of the material terms of the PRV Transfer Agreement does not purport to be complete and is qualified in its

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001193125-22-314755

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.